RxDoctor Payments Data

Jayde Kurland, MD

Gastroenterology · Lima, OHNPI 1992785430

Payments from drug & device makers

$23,865in general payments, 2019–2025

Across 1,122 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Phathom Pharmaceuticals, Inc.$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Lucid Diagnostics Inc.$1K
  • Boston Scientific$1K
  • plus $8K from 41 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Consulting fees$30%
  • Speaking & faculty fees$4,15017%
  • Travel & lodging$5912%
  • Food & beverage$19,03780%
  • Education$840%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,865 in reported general payments places this provider in the 80th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$184,266
Medicare patients
395
Services billed
3,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase16$71,710
LinzessLinaclotide29$44,731
Mesalamine ErMesalamine17$5,031
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates70$4,421
Omeprazole235$2,079
Sucralfate24$1,799
Colestipol Hcl29$1,750
Pantoprazole Sodium115$1,721
CholestyramineCholestyramine (With Sugar)17$1,127
Famotidine49$414
Rabeprazole Sodium12$332
ValacyclovirValacyclovir Hcl12$253
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$127
Nortriptyline Hcl11$105
Dicyclomine Hcl12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$43$71,71016 claims
AbbVieLinzess$4,569$44,73129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →